Asset

  • No.

    88

  • Asset Title

    Nuclear Import (KPNB1)_Cancer

  • Organization

    CD3

  • Product Type

    Small molecule

  • Therapeutic Area

    Oncology

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    Elevated expression of diverse importins and exportins (KPNA2, KPNB1, XPO1, XPO2) has been documented in many different cancer cells. Further, down-regulation of KPNA2, KPNB1 and XPO1 inhibited cancer cell proliferation. The inhibitors in development can selectively inhibit KPNA2/7 to restrict nuclear transport of cMYC and other oncogenic factors essential for robust activation of cancer cell survival signaling pathway

  • Researcher

  • Patent

  • Publication

  • Attachment

TOP